Australian life-sciences firm Invion is leading the global clinical development of a novel PhotoDynamic Therapy (PDT) for cancer. Invion has developed over 300 unique patent protected compounds based on the PhotosoftTM Technology.
Invion is a clinical-stage life-science company that is leading the global research and development of the Photosoft technology for the treatment of a range of cancers and infectious diseases in human and animal health. Invion holds the exclusive global rights to the Photosoft technology for multiple cancer indications. It also holds the exclusive world-wide rights to the technology for Human Papilloma Virus (HPV), Periodontal (human and animal) and Non-Cancer Eye Diseases.
Invion is partnering with world leading research institutes, such as the Peter MacCallum Cancer Centre and Hudson Institute of Medical Research, to develop a novel photosensitiser that will improve the treatment of skin cancers and hard-to-treat solid cancers. Photosoft aims to be more effective at targeting and killing cancers without harmful side effects and minimal discomfort.